NASDAQ
27.06.25 | 21:59
12,760 US-Dollar
+1,67 % +0,210
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.06. | LENSAR, Inc.: LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 46 | GlobeNewswire (Europe) | ORLANDO, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted... ► Artikel lesen | |
| 27.05. | FTC Requests More Information on Alcon's $430 Million Acquisition of Lensar | 13 | CPI | ||
| 22.05. | LENSAR, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | LENSAR, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| LENSAR Aktie jetzt für 0€ handeln | |||||
| 08.05. | LENSAR, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.05. | LENSAR, Inc.: LENSAR Reports First Quarter 2025 Results and Provides Business Update | 77 | GlobeNewswire (Europe) | 14 ALLY Robotic Laser Cataract Systems ("ALLY Systems") placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first... ► Artikel lesen | |
| 25.03. | ALC Stock Rises Following the Merger Agreement With LENSAR | 1 | Zacks | ||
| 24.03. | BTIG cuts LENSAR stock rating post Alcon acquisition deal | 5 | Investing.com | ||
| 24.03. | M&A Snapshot: Alcon to acquire LENSAR to boost its cataract equipment portfolio | 6 | Seeking Alpha | ||
| 24.03. | Alcon agrees to acquire Lensar and its robotic cataract laser system | 3 | MassDevice | ||
| 24.03. | Alcon Agrees To Acquire LENSAR For Up To Approximately $430 Mln | 479 | AFX News | WASHINGTON (dpa-AFX) - Eye care company Alcon, Inc. (ALC) and medical technology company LENSAR, Inc. (LNSR) announced Monday the companies have entered into a definitive merger agreement through... ► Artikel lesen | |
| 24.03. | Alcon übernimmt Medtech-Unternehmen Lensar für bis zu 430 Millionen Dollar | 633 | Moneycab | Genf - Der Augenheilkundespezialist Alcon kauft in den USA zu. Für bis zu 430 Millionen Dollar übernimmt das Genfer Unternehmen das Medizintechnikunternehmen Lensar aus den USA. Lensar ist laut einer... ► Artikel lesen | |
| 24.03. | Alcon agrees to acquire LENSAR for $14.00 per share | 6 | Seeking Alpha | ||
| 24.03. | Alcon übernimmt LENSAR für bis zu 430 Millionen US-Dollar | 5 | Investing.com Deutsch | ||
| 24.03. | LENSAR, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.03. | Alcon Agrees to Acquire LENSAR, Inc. | 370 | Business Wire | Acquisition of ALLY Robotic Cataract Laser Systems strengthens Alcon's cataract equipment and technology portfolio Next generation technology will be expanded globally, improving the efficiency... ► Artikel lesen | |
| 06.03. | LENSAR - Top Healthcare Equipment Stock | 4 | Barchart.com | ||
| 04.03. | LENSAR, Inc.: LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 120 | GlobeNewswire (Europe) | ORLANDO, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors... ► Artikel lesen | |
| 28.02. | LENSAR, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 10 | SEC Filings | ||
| 27.02. | LENSAR, Inc. - 10-K, Annual Report | 1 | SEC Filings |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARL ZEISS MEDITEC | 57,00 | +1,06 % | Carl Zeiss Meditec AG: Chirurgische Präzision, strategische Genauigkeit; mwb research stuft auf KAUFEN | Carl Zeiss Meditec (CZM) bleibt ein weltweit führender Anbieter in der Augenheilkunde und Mikrochirurgie, gestützt durch strukturelle Wachstumstreiber wie demografischen Wandel und die Zunahme von Sehstörungen.... ► Artikel lesen | |
| ROKU | 73,28 | -1,32 % | This 30-second fix made my Roku TV run like new again (and why it works) | ||
| HIMS & HERS HEALTH | 42,410 | +0,43 % | Kein Wegovy mehr: Novo Nordisk bricht Partnerschaft: Hims & Hers-Aktie fällt ins Bodenlose! | © Foto: Christian Schultz/dpaNovo Nordisk bricht mit Hims & Hers: Beide Aktien fallen drastisch, wobei der Telemedizinanbieter aus den USA den Kürzeren zieht.Tiefschlag für die Anteilsscheine von Hims... ► Artikel lesen | |
| MEDICLIN | 3,020 | -1,31 % | EQS-News: MEDICLIN AG: Ordentliche Hauptversammlung stimmt allen Beschlussvorschlägen zu | EQS-News: MEDICLIN AG
/ Schlagwort(e): Hauptversammlung
MEDICLIN AG: Ordentliche Hauptversammlung stimmt allen Beschlussvorschlägen zu
04.06.2025 / 13:27 CET/CEST
Für... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Windtree Therapeutics: Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel | Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of... ► Artikel lesen | |
| EMEIS | 10,650 | +0,28 % | emeis 2025 Annual General Meeting | Summary of Voting Results
Regulatory News:
emeis (Paris:EMEIS):
Guillaume Pepy, Chairman of the Board of Directors:"Today, we are particularly proud to announce, together with the Board... ► Artikel lesen | |
| VERU | 0,565 | +9,51 % | Veru Inc.: Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation | --During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study... ► Artikel lesen | |
| LIFEWARD | 0,638 | +9,68 % | Lifeward Ltd.: Administrative Law Judge Determines ReWalk Personal Exoskeleton is "Reasonable and Necessary" for Medicare Beneficiary | MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 24, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business Update | Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual MeetingGranted Orphan Drug designation by FDA for TPST-1495 for the treatment... ► Artikel lesen | |
| SENSEONICS | 0,446 | +5,64 % | Senseonics lays out hopes for next-gen CGM commercial timelines | ||
| CLOVER HEALTH INVESTMENTS | 2,382 | +1,93 % | Canaccord Genuity Keeps Buy Rating on Clover Health (CLOV) | ||
| BONESUPPORT | 25,760 | 0,00 % | Bonesupport Holding AB: Upcoming CEO change. Emil Billbäck will transfer to a role as Senior Advisor. Torbjörn Sköld will start as CEO effective September 1st, 2025 | BONESUPPORT, a leading company in orthobiologics for the management of bone injuries, today announces the coming transition of leadership at Bonesupport.
Lennart Johansson states: Emil Billbäck will... ► Artikel lesen | |
| EKSO BIONICS | 3,400 | -4,76 % | XFRA 23E0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILEKSO BIONICS. NEW... ► Artikel lesen | |
| SURGICAL SCIENCE SWEDEN | 14,070 | -0,07 % | Surgical Science Sweden AB: Interim report January - March 2025: Strong growth despite macroeconomic uncertainties | First quarter 2025 (Jan-Mar)
Net sales amounted to SEK 250.7 (188.2) million, an increase of 33 percent compared with the corresponding period in the preceding year. SEK 18.3 million was acquired revenue.License... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 46,900 | +0,13 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen |
LENSAR INC gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von +0,210 (+1,67 %) liegt der Kurs bei 12,760 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LENSAR INC finden Sie auf Wallstreet Online.